The Race Oncology (ASX:RAC) share price is stumbling today

The pharmaceutical company's shares are losing ground. Let's look at its new contract award.

| More on:
A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Race Oncology Ltd (ASX: RAC) share price is falling today after the pharmaceutical company announced a contract award for a leukemia trial.

Race Oncology has signed up a leading Israeli company to supply drugs and provide other clinical services for its phase 2 relapsed/refractory acute myeloid leukemia (AML) trial.

AML is a type of blood cancer that starts in the bone marrow, and usually moves into the blood stream. While treatment options are limited, if not addressed, AML can be life-threatening.

At the time of writing, Race Oncology shares are swapping hands for $3.73, down 1.06%.

What has Race Oncology announced?

The Race Oncology share price is losing ground today despite the company's latest upbeat announcement.

In today's release, Race advised it has entered into a contract with Israel's leading pharmaceutical distributor, Trialog Clinical Trials. The agreement will see Trialog deliver trial drugs, including Bisantrene, and provide other clinical services. Bisantrene is a small-molecule anti-cancer drug being developed by Race for the treatment of AML.

Race Oncology is scheduled to run its phase 2 AML trial at the Chaim Sheba Medical Centre in Israel. The study will use Bisantrene in a novel three-drug combination to show its superior efficacy in AML cells. The trial involves 29 participants, with the first patient due to receive treatment in the third quarter of the calendar year.

The company said the supply agreement will cost a maximum of about US$800,000. This is expected to cover the patient enrolment period from 2021 to 2023.

Furthermore, the phase 2 AML trial will run alongside an Australian phase 2 trial in patients with extramedullary AML. The latter is planned to begin in the fourth quarter of 2021.

Extramedullary AML is considered a rare and serious illness with about a 25% survival rate over a 5-year term. The disease occurs when the leukaemia spreads from the bone marrow and forms solid tumours in tissues such as the skin, breast, kidney, brain, or other organs.

About the Race Oncology share price

Race Oncology shares have gained more than 1,000% in the past 12 months and are up by more than 110% year to date.

Based on today's price, Race Oncology has a market capitalisation of about $542 million, with 143 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »